Tosedostat-d5

Modify Date: 2024-01-10 19:21:17

Tosedostat-d5 structure	Common Name	Tosedostat-d5
	CAS Number	1217844-03-5	Molecular Weight	411.50
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₁H₂₅D₅N₂O₆	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Tosedostat-d5

Tosedostat-d5 (CHR-2797-d5) is the deuterium labeled Tosedostat. Tosedostat (CHR-2797) is an orally active aminopeptidase inhibitor. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines[1][2].

Name	Tosedostat-d5

Description	Tosedostat-d5 (CHR-2797-d5) is the deuterium labeled Tosedostat. Tosedostat (CHR-2797) is an orally active aminopeptidase inhibitor. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Aminopeptidase
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Krige D, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68(16):6669-79. [3]. Jenkins C, et al. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leuk Res. 2011 May;35(5):677-81. [4]. Smith EM, et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget. 2015 Jul 10;6(19):17314-27.

Molecular Formula	C₂₁H₂₅D₅N₂O₆
Molecular Weight	411.50